Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

Summary

This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.

Timeline

Start

2017-07-19

Primary completion

2019-03-19

Completion

2019-03-19

Publications

• Shaw CA, August A, Bart S, Booth PJ, Knightly C, Brasel T, Weaver SC, Zhou H, Panther L. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine. 2023 Jun 13;41(26):3898-3906. doi: 10.1016/j.vaccine.2023.04.064. Epub 2023 May 18.

Drugs

Indications